# Situation: A 72-year-old woman with Parkinson disease for 9 years is admitted to the medical ward with community-acquired pneumonia. At home she takes carbidopa-levodopa 25/100 mg by mouth at 06:00, 10:00, 14:00, and 18:00. She has no drug allergies. She asks why her levodopa is combined with carbidopa. What is the reason?

> source: MyMerci (mymerci.kr)  
> url: https://mymerci.kr/pages/nclex_q.php?qn_id=630320  
> language: ko  
> subject: Nursing Practice IV — Care of Clients with Problems in Nutrition and Gastrointestinal, Metabolism and Endocrine, Perception and Coordination

## 문제

Situation: A 72-year-old woman with Parkinson disease for 9 years is admitted to the medical ward with community-acquired pneumonia. At home she takes carbidopa-levodopa 25/100 mg by mouth at 06:00, 10:00, 14:00, and 18:00. She has no drug allergies.

She asks why her levodopa is combined with carbidopa. What is the reason?

## 보기

1. It stimulates dopamine receptors directly in the basal ganglia
2. It stops levodopa from turning into dopamine outside the brain **✔ 정답**
3. It blocks monoamine oxidase type B so dopamine lasts longer
4. It slows levodopa breakdown by catechol-O-methyltransferase

**정답: 2**

## 해설

Carbidopa blocks peripheral dopa decarboxylase, so less levodopa is converted to dopamine outside the brain. More levodopa reaches the brain, and peripheral effects such as nausea and orthostatic hypotension are reduced. The other options describe catechol-O-methyltransferase inhibitors, monoamine oxidase type B inhibitors, and dopamine agonists.

## 심화 해설

Why carbidopa is combined with levodopa

Levodopa is the most effective drug for replacing dopamine in Parkinson disease, but when given alone, most of an oral dose is converted to dopamine before it ever reaches the brain. This peripheral conversion is driven by the enzyme dopa decarboxylase, which is abundant in the gut wall, liver, and systemic circulation. The resulting peripheral dopamine cannot cross the blood–brain barrier, so it contributes little to motor benefit while producing unwanted effects such as nausea, vomiting, and orthostatic hypotension.

Carbidopa is a peripheral dopa decarboxylase inhibitor. Because it does not cross the blood–brain barrier in clinically meaningful amounts, it acts only outside the central nervous system. When carbidopa is coadministered with levodopa, it blocks the conversion of levodopa to dopamine outside the brain, allowing a larger fraction of each dose to enter the central nervous system intact. This means a lower total levodopa dose can achieve the same brain effect, and the peripheral dopamine-related adverse effects are reduced.

The rationale is therefore not that carbidopa stimulates dopamine receptors, nor that it inhibits monoamine oxidase type B (MAO-B) or catechol-O-methyltransferase (COMT). Those are separate drug classes used as adjuncts in Parkinson disease. Key point! Carbidopa is a decarboxylase inhibitor, not a dopamine agonist, MAO-B inhibitor, or COMT inhibitor.

| Drug class | Example | Primary mechanism |
| --- | --- | --- |
| Peripheral decarboxylase inhibitor | Carbidopa, benserazide | Blocks levodopa conversion to dopamine outside the brain |
| Dopamine agonist | Pramipexole, ropinirole | Directly stimulates dopamine receptors in the basal ganglia |
| MAO-B inhibitor | Selegiline, rasagiline | Slows central dopamine breakdown so dopamine lasts longer |
| COMT inhibitor | Entacapone, opicapone | Slows peripheral levodopa breakdown by COMT |

The pharmacokinetic rationale is reinforced by evidence on levodopa absorption. Levodopa has a short half-life and a narrow absorption window in the proximal small intestine [2]. Because only a limited portion of each oral dose is absorbed before transit moves the drug beyond its optimal uptake site, any strategy that preserves levodopa in its active parent form is clinically important. By inhibiting peripheral decarboxylation, carbidopa increases the bioavailability of levodopa to the brain without requiring a higher oral dose .

In the patient described here, the carbidopa-levodopa 25/100 mg regimen is a standard immediate-release formulation. The 25 mg of carbidopa is sufficient to inhibit peripheral dopa decarboxylase, while the 100 mg of levodopa provides the therapeutic dopamine precursor. The four-times-daily schedule reflects the short duration of action of immediate-release levodopa, which is a recognized limitation of standard therapy [2].

A separate consideration is that long-term levodopa/decarboxylase inhibitor therapy shifts levodopa metabolism toward O-methylation, which can impair methylation capacity and increase oxidative stress . This does not change the fundamental role of carbidopa, but it explains why COMT inhibitors are sometimes added later in the disease course. Watch out! Do not confuse the role of carbidopa with that of entacapone. Carbidopa blocks decarboxylation; entacapone blocks O-methylation. Both increase levodopa delivery to the brain, but through different enzymes.

The correct answer is therefore option 2: carbidopa stops levodopa from turning into dopamine outside the brain, which increases central levodopa availability and reduces peripheral dopaminergic side effects.References (research sources)

- [2]IPX203 vs Immediate-Release Carbidopa-Levodopa for the Treatment of Motor Fluctuations in Parkinson Disease: The RISE-PD Randomized Clinical Trial.RCT/clinical trialHauser RA, Espay AJ, Ellenbogen AL, Fernandez HH, Isaacson SH, LeWitt PA (2023) · DOI: 10.1001/jamaneurol.2023.2679

## 임상 시나리오

Carbidopa-Levodopa Combination RationaleWhy Parkinson regimens pair levodopa with a decarboxylase inhibitor
Levodopa is converted to dopamine by dopa decarboxylase in the gut, liver, and circulation before it reaches the brain. Peripheral dopamine cannot cross the blood-brain barrier, causing nausea and orthostatic hypotension without motor benefit.

Carbidopa inhibits peripheral dopa decarboxylase only, allowing more levodopa to enter the CNS intact. This permits a lower total levodopa dose for the same therapeutic effect and reduces peripheral side effects.

CautionCarbidopa is not a dopamine agonist, MAO-B inhibitor, or COMT inhibitor. Do not confuse it with selegiline, rasagiline, entacapone, pramipexole, or ropinirole.

## 핵심 개념

- **dopa decarboxylase** — Enzyme that converts levodopa to dopamine in peripheral tissues and the brain
- **carbidopa** — Peripheral dopa decarboxylase inhibitor that does not cross the blood-brain barrier
- **levodopa** — Dopamine precursor that crosses the blood-brain barrier and is converted to dopamine centrally
- **MAO-B inhibitor** — Drug class that blocks monoamine oxidase type B to prolong dopamine action in the brain
- **COMT inhibitor** — Drug class that blocks catechol-O-methyltransferase to reduce peripheral levodopa breakdown

## 같은 주제 문제

- [Situation: A 68-year-old man is on the medical ward on day 4 after an ischemic stroke in t…](https://mymerci.kr/pages/nclex_q.php?qn_id=630316)
- [Situation: A 68-year-old man is on the medical ward on day 4 after an ischemic stroke in t…](https://mymerci.kr/pages/nclex_q.php?qn_id=630317)
- [Situation: A 68-year-old man is on the medical ward on day 4 after an ischemic stroke in t…](https://mymerci.kr/pages/nclex_q.php?qn_id=630318)
- [Situation: A 68-year-old man is on the medical ward on day 4 after an ischemic stroke in t…](https://mymerci.kr/pages/nclex_q.php?qn_id=630319)
- [Situation: A 72-year-old woman with Parkinson disease for 9 years is admitted to the medic…](https://mymerci.kr/pages/nclex_q.php?qn_id=630321)
- [Situation: A 72-year-old woman with Parkinson disease for 9 years is admitted to the medic…](https://mymerci.kr/pages/nclex_q.php?qn_id=630322)
- [Situation: A 72-year-old woman with Parkinson disease for 9 years is admitted to the medic…](https://mymerci.kr/pages/nclex_q.php?qn_id=630323)
- [Situation: A 30-year-old man with a complete spinal cord injury at the sixth cervical (C6)…](https://mymerci.kr/pages/nclex_q.php?qn_id=630324)

---

More free questions: [기출문제](https://mymerci.kr/)

_학습 참고용입니다. 실제 임상은 최신 지침과 소속 기관 프로토콜을 따르세요._